BUZZ-Aeterna Zentaris Inc: Licenses lead drug

Fri Jul 1, 2016 10:28am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drug developer's U.S.-listed shares up 15 pct at $3.75

** Company says signed license agreement with Orient EuroPharma's unit for commercializing its lead experimental anti-cancer drug, Zoptrex, in Taiwan and nine countries in Southeast Asia

** Company will also license intellectual property related to Zoptrex

** Orient has also agreed to make additional payments and royalties to the company upon achieving regulatory and commercial milestone

** Up to Friday's close, stock had fallen 27 pct this year